{"request_id":"fd16b9201ecb0191c38483f4432ec2a1","results":{"ticker":"AMGN","name":"Amgen Inc","market":"stocks","locale":"us","primary_exchange":"XNAS","type":"CS","active":true,"currency_name":"usd","cik":"0000318154","composite_figi":"BBG000BBS2Y0","share_class_figi":"BBG001S5NNL6","market_cap":174459290532.24002,"phone_number":"(805)447-1000","address":{"address1":"ONE AMGEN CENTER DRIVE","city":"THOUSAND OAKS","state":"CA","postal_code":"91320"},"description":"Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.","sic_code":"2836","sic_description":"BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)","ticker_root":"AMGN","homepage_url":"https://www.amgen.com","total_employees":26700,"list_date":"1983-06-17","branding":{"logo_url":"https://api.polygon.io/v1/reference/company-branding/YW1nZW4uY29t/images/2024-08-01_logo.svg","icon_url":"https://api.polygon.io/v1/reference/company-branding/YW1nZW4uY29t/images/2024-08-01_icon.jpeg"},"share_class_shares_outstanding":536440000,"weighted_shares_outstanding":536434692,"round_lot":100},"status":"OK"}
